Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECIDE: Daclizumab HYP vs Avonex in RRMS
NCT01064401Phase 3Completed
- Sponsor
- Biogen
- Start
- May 2010
- Primary completion
- Mar 2014
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of daclizumab in relapsing-remitting multiple sclerosis (RRMS), sponsored by Biogen. Started May 2010; status: completed.
02
Drugs
daclizumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01064401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01064401.